/
PCRX
$25.37+$0.28 (+1.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$993.1M
39M shares
52-week range
$18.80 – $27.64
74% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-34.61
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $337.3M | $421.0M | $429.6M | $541.5M | $666.8M | $675.0M | $701.0M | $726.4M |
| Cost of revenue | $86.8M | $106.7M | $117.3M | $140.3M | $199.3M | $184.7M | $170.4M | $149.7M |
| Gross profit | $250.4M | $314.3M | $312.3M | $401.3M | $467.5M | $490.3M | $530.5M | $576.7M |
| Gross margin | 74.3% | 74.7% | 72.7% | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| R&D | $55.7M | $72.1M | $59.4M | $55.5M | $84.8M | $76.3M | $81.6M | $117.3M |
| Operating income | $15.9M | $10.5M | $46.4M | $89.9M | $60.0M | $87.7M | −$73.4M | $33.3M |
| EBITDA | $33.1M | $30.7M | $63.5M | $113.9M | $140.4M | $154.6M | $29.1M | $122.5M |
| Net income | −$471.0K | −$11.0M | $145.5M | $42.0M | $15.9M | $42.0M | −$99.6M | $7.0M |
| Net margin | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% |
| EPS (diluted) | -0.01 | -0.27 | 3.33 | 0.92 | 0.34 | 0.89 | -2.15 | 0.16 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $768M | $2.88 | $2.79–$2.97 | 3 |
| 2027 | $831M | $3.61 | $3.30–$3.92 | 3 |
| 2028 | $954M | $4.85 | $4.80–$4.88 | 1 |
| 2029 | $925M | $4.89 | $4.84–$4.92 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$351.95
Price
$25.37
Implied upside
+1287%
Peer comparison
Pacira BioSciences, Inc. Common Stock
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
www.pacira.com- Employees
- 829
- IPO / List date
- Feb 3, 2011
- HQ
- BRISBANE, CA
Held by traders on TradeandTell
No one on the platform currently holds PCRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,825,501 | $41.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PCRX yet.
